Extract
Note: Please read the
complete full text with Figures and Tables at
Introduction
The accumulation of aluminum (Al)
within the body can result in many mental diseases. For example, Al
is concentrated in the neurofibrillary tangles and senile plaques of
patients with Alzheimer disease (AD)[1]. Al can be
attributed to several neurological disorders, such as dialysis
syndrome and Guamanian amylotrophic lateral sclerosis-Parkinson's
dementia[2]. A number of studies have implicated that Al
has no effect on long-term potentiation (LTP)[3].
However, more and more studies have shown that Al can impair LTP[4]
and evoke potential in the hippocampus[5]. Studies have
also shown that Al affects amino acid neurotransmitters in the
hippocampus and enhances glutamate-mediated excitotoxi-city, which
may be one of the causes of its toxicity[6]. Reports
about its mechanism involving ion channels are few and controversial[7-9].
Extracts from leaves of Ginkgo
biloba (EGb) and one of its constituents ginkgolide B
have been demonstrated to protect cardiomyocytes and cultured
neurons from the injury induced by hypoxia, ischemia, and the
neurotoxicity induced by A¦Â[10-12].
However, it is not known whether the mechanism of this protection of
neurons involves ion channels, such as voltage-dependent calcium
channels (VDCC).
The present study investigated the
actions of Al on IHVA and its modulation by Gin B
to examine the neurotoxic mechanisms of Al and the neuroprotective
mechanisms of Gin B.
¡¡
Materials and methods
Reagents
Pronase E, forskolin, TEA-Cl, H-89, and
HEPES were purchased from Sigma Chemical Company (St Louis, MO,
USA). H-89 was dissolved in pipette solution and stored at -20¡ãC.
After the whole-cell configuration was constructed, H-89 was
dialyzed into the cell through the pipette. Ginkgolide B (BN52021,
purity 98.2%) was from the Wuhan Institute of Botany, Chinese
Academy of Sciences (Wuhan, China). AlCl3 was from
Jinghua Chemical Company (Beijing, China). The remaining chemicals,
unless otherwise stated, were all purchased from the Shanghai
Chemical Reagent Plant (Shanghai, China).
Cell isolation Animals were
provided by the experimental animal center of Tongji Medical College
(Grade II, Certificate No 19-050). Hippocampal CA1 neurons
were acutely isolated by enzymatic digestion and mechanical
dispersion from 7 to 10-d-old Wistar rats as described in a previous
study[13], with a few modifications. After the
animals were killed, the hippocampi were removed and coronary slices
were cut at a thickness of approximately 500 mm in ice-cold
oxygenated incubation solution within 30 s. The slices were
incubated in an external solution saturated with pure O2
at 32 ¡ãC for 1 h, treated with Pronase E 6.0-7.0 kU/L for 25 min in
the oxygenated external solution at 32 ¡ãC. After digestion the
slices were washed six times with external solution and incubated in
the same solution saturated with pure O2 at room
temperature. CA1 regions were dissected out and transferred into
centrifuge tubes. Hippocampal neurons were dispersed by gentle
pipetting using fine glass tubes. After 5 min, the cell suspension
was transferred into the recording chamber with a glass coverslip
filled with external solution. The cells were left for approximately
30 min before beginning the experiments.
Electrophysiology The cells
were placed in a recording chamber mounted on the stage of an
inverted microscope (Carl Zeiss, Germany) and superfused with extra
cellular solution at room temperature (21-22 ¡ãC). Extracellular
solution for recording IHVA was composed of
(mmol/L): NaCl 150, KCl 5, MgCl2 1.1, CaCl2
2.5, HEPES 10, glucose 10, TTX 0.001, and the pH was adjusted to 7.4
with NaOH. Extracellular application of drugs was carried out by
perfusing cells with extracellular solution containing the drugs.
Whole-cell patch experiments were
carried out using an Axopatch 200A amplifier (Axon Instruments,
Foster City, CA, USA) driven by ISO2 software (MFK, Frankfurt,
Germany). In the voltage-clamp experiments, the cells were stepped
from -80 mV (50 ms) to -40 mV (200 ms), and then depolarized to 0 mV
(200 ms) after briefly hyperpolarizing the membrane potential for 10
ms to -45 mV. The IHVA was activated by the second
depolarization. The protocol was applied every 5 s. For analysis of
the current-voltage (I-V) relationship, voltage steps (200
ms) were used to depolarize from -40 mV to +40 mV in 10 mV
increments. Glass pipettes were used with a resistance of about 3-5
MW when filled with a pipette solution composed of (mmol/L): CsCl
140, MgCl2 2, Mg-ATP 4, TEA-Cl 2, HEPES 10, egtazic acid
11, and the pH was adjusted to 7.2 with CsOH.
Data were acquired at a sampling
rate of 10 kHz, filtered at 2 kHz, stored on hard disk and analyzed
off-line using the ISO2 analysis software package (MFK, Frankfurt,
Germany).
Data analysis The amplitude
of IHVA was calculated as the difference between
the instantaneous current at the beginning of the experiment and the
maximum activating current. Currents were normalized to membrane
capacitance to calculate current densities (pA¡¤pF-1).
Cell membrane capacitance (Cm) was determined online using the ISO2
software program. The activation rate constant and inactivation rate
constant were obtained using the ISO2 analysis software. Graphical
and statistical data analyses were carried out using Sigmaplot 2001
(SPSS, Chicago, IL, USA) and Origin 6.0 (Microcal Software, Inc,
Northampton, MA01060, USA). Data were presented as mean¡ÀSEM where
appropriate. Statistical analysis were carried out using Student's
paired and unpaired t-tests and values of P<0.05 were
considered statistically significant.
¡¡
Results
Action of Al on IHVA
Bath application of AlCl3
0.01 mmol/L had no effect on IHVA.
The current densities before and after AlCl3 application
were 18.5¡À2.4 pA¡¤pF-1 and 18.5¡À2.2
pA¡¤pF-1, respectively (n=11, P>0.05)
(Figure 1A).
Bath application of AlCl3
0.1 mmol/L caused a reduction in IHVA from
17.7¡À1.6 pA¡¤pF-1 to 12.7¡À1.4 pA¡¤pF-1 (n=27,
P<
0.01), that is, a reduction of 30.5%¡À 4.1%. The reduction of IHVA
by AlCl3 did not recover after the AlCl3 was
washed out (Figure 1B).
AlCl3 0.25 mmol/L
caused a reduction in IHVA in 80% (8/15) of
the neurons, and an increase in 20% (4/15) of the neurons. AlCl3
0.50 mmol/L caused a reduction in IHVA in
50% (7/14) of the neurons, and an increase in IHVA
in 50% (7/14) of the neurons. In contrast, AlCl3 0.75
mmol/L increased IHVA by 30.8%¡À5.2% (n
=15, P<0.01) in all neurons tested (from 17.8¡À
1.8 pA¡¤pF-1 to 23.0¡À2.5 pA¡¤pF-1). AlCl3
1.0 mmol/L increased IHVA by 37.3%¡À7.8%
(from 19.6¡À3.1 pA¡¤pF-1 to 26.2¡À4.3 pA¡¤pF-1)
(n=21, P<0.01). IHVA increased
by AlCl3 was irreversible after AlCl3
was washed out (Figure 1C).
At both low and high concentrations,
AlCl3 inhibited or increased the maximum amplitude of
IHVA, but had no effect on the activation threshold
potential of IHVA in the I-V
relationship (Figure 2A, B). The G-V curve was unaffected by
AlCl3 0.1 mmol/L (n=5, P>0.05) or AlCl3
1.0 mmol/L (n=5,
P>0.05) (control: V0.5=-12.8 mV¡À4.4 mV, k=5.5¡À3.8;
AlCl3 0.1 mmol/L: V0.5=-12.0 mV¡À4.5 mV,
k=5.0¡À4.0; AlCl 3 1.0 mmol/L: V0.5=-13.6
mV¡À5.3 mV, k=5.2¡À4.4) (Figure 2C). In addition, AlCl3 had no
effect on the activation rate constants at concentrations of 0.1
mmol/L (n=8, P>0.05) or 1.0 mmol/L (n=9, P>0.05).
To gain a better understanding of
the action of Al on IHVA, we explored
its action on the steady-state inactivation curve of IHVA.
AlCl3 shifted the curve to a depolarizing voltage at
1.0 mmol/L (n=5, P<0.05), whereas it
shifted the inactivation curve to a hyperpolarizing voltage at 0.1
mmol/L (n=5, P<
0.05). (Control: V0.5=-35.4¡À3.3 mV, k=-14.3¡À2.5;
0.1 mmol/L AlCl3: V0.5=-41.1¡À2.7 mV,
k=-9.2¡À2.0; 1.0 mmol/L AlCl3: V0.5=
-29.8¡À6.9 mV, k=-10.8¡À2.4). AlCl3 0.1 mmol/L
decreased the inactivation rate constant by 27.3%¡À6.3% (n=5,
P<0.01), whereas 1.0 mmol/L AlCl3 increased the
inactivation rate constant by 44.7%¡À3.4% (n=7, P<0.01)
(Figure 3).
Effect of Gin B on IHVA
in hippocampal neurons Gin B at doses of 0.01-20 µmol/L had no
effect on IHVA in normal hippocampal neurons (P>0.05)
(Table 1). Gin B inhibited the increase of IHVA by
AlCl3 1.0 mmol/L. After a steady increase in the action
of AlCl3, Gin B at concentrations of 0.01 µmol/L,
0.1µmol/L, 1.0 µmol/L, and 10 µmol/L reduced IHVA
by
21.0%¡À4.6% (n=7, P<0.05), 57.9%¡À7.8% (n=6, P<0.01),
79.3%¡À2.7% (n=6, P<0.01), and 82.4%¡À7.3% (n=6,
P<0.05), respectively. The concentration producing 50%
inhibition by Gin B of Al 1.0 mmol/L is 0.0359
µmol/L¡À0.0038 µmol/L (Figure 4).
Co-superfusion AlCl3 0.1
mmol/L plus Gin B 10 µmol/L was applied in the same way as AlCl3
1.0 mmol/L. For all tested neurons (n=15), there was no
change in IHVA in 53.3% of the neurons and a
slight increase in IHVA in the remaining neurons (P>0.05).
This result indicated that Gin B had no effect on the action of Al
0.1 mmol/L .
Mechanism of action of high
concentrations of Al on IHVA Application of
forskolin 10 µmol/L (an agonist of adenylyl cyclase) increased IHVA
by 30.8%¡À7.5% (n=14, P<
0.05). Bath application of forskolin 10 µmol/L in combination with
Al 1.0 mmol/L increased IHVA by 68.3%¡À8.7% (n=31,
P<
0.05) (Figure 5A).
H-89 is a selective antagonist of
PKA. In this study, adding H-89 in the pipette solution reduced the
amplitude of IHVA by 42.0%¡À4.1% (from 20.2¡À3.3
pA¡¤pF-1 to 13.9¡À3.1 pA¡¤pF-1, n=6, P<0.01)
within approximately 80-100 s. AlCl3
1.0 mmol/L was bath applied in the presence of H-89 (10 µmol/L) in
the pipette solution. Aluminum increased IHVA by
17.2%¡À5.8% (n=10, P<0.05). Compared with the effect of
Al 1.0 mmol/L on IHVA without H-89 (n=29,
P<0.05), the reduction in IHVA
in the presence of H-89 was significant, indicating that H-89 could,
in part, abolish the increase in IHVA by Al at
high concentrations (Figure 5B).
Mechanism of action of low
concentrations of Al on IHVA To investigate
the mechanism by which Al inhibited IHVA at low
concentrations, AlCl3 0.1 mmol/L was applied
first and IHVA was reduced to 12.9¡À1.1 pA¡¤pF-1
from 18.5¡À1.7 pA¡¤pF-1 (n=12, P<0.01).
After the current was stable, fors-kolin 10 µmol/L and
AlCl3 0.1 mmol/L were co-applied. Fors-kolin did not
cancel the inhibition of IHVA by 0.1 mmol/L AlCl3.
The IHVA after forskolin application was 12.5¡À0.9
pA¡¤pF-1 (n=12, P>0.05) (Figure 6A).
In the presence of H-89 (10 mmol/L),
IHVA was reduced to 13.1¡À2.5 pA¡¤pF-1
from 20.1¡À4.2 pA¡¤pF-1 (n=8, P<0.01). After
the current was stable, AlCl3 0.1 mmol/L was
bath applied, and IHVA was reduced to 12.5¡À2.5
pA¡¤pF-1. There was no difference in the percentage
inhibition with and without H-89 application (n=33, P>0.05)
(Figure 6B).
¡¡
Discussion
VDCC in hippocampal neurons are
divided into high voltage-dependent channels (HVA) and low
voltage-dependent channels (LVA) according to the difference in
activation threshold. In the present study we demonstrated that the
effect of Al on IHVA differed at different
concentrations. Al reduced the amplitude of IHVA
irreversibly at low concentrations (0.1 mmol/L). This result
supports a previous report on dorsal root ganglion (DRG) neurons[7].
However, Al inhibited and enhanced IHVA as Al
concentrations increased (between 0.25 mmol/L and 0.50 mmol/L), and
the percentage of enhanced IHVA by Al
in the neurons examined increased with increased Al concentrations.
When 0.75 mmol/L and 1.0 mmol/L Al were bath applied, the amplitude
of IHVA in all neurons tested increased.
The toxic effect of Al in humans is
chronic and accumulative and leads to degradation and apoptosis of
cells[14]. Acute application of Al inhibits LTP on
hippocampal slices of rats as well as in vivo by
intracerebroventricular injection. Studies have shown that a
series of molecular mechanisms involved in synaptic plasticity,
including protein phosphorylation, gene expression, and
neurotransmitter release, were regulated by VDCC[15]. LTP
induced in different areas of the hippocampus has an intimate
relationship with VDCC[16]. The inhibition of IHVA
by Al at low concentrations could lead to a reduction in calcium
influx, resulting in the reduced release of some neurotransmitters,
which might explain impaired LTP in this concentration range.
Aluminum increased the amplitude of IHVA at high
concentrations and, thus, led to increased calcium influx, resulting
in a series of pathological changes, which could cause impairment of
LTP and neuronal damage.
In our study, the actions of Al on
IHVA differed at different concentrations; thus,
it is possible that the mechanism of action is different at
different Al concentrations. Protein phosphorylation
modulates the function of VDCC and the AC-cAMP-PKA system plays a
key role[17]. Thus, forskolin and H-89 were used to
investigate whether the action of Al on IHVA is
involved in this mechanism. H-89 markedly abolished the increase of
IHVA by Al 1.0 mmol/L. Co-superfusion with
forskolin plus Al at high concentrations caused more Ca2+
influx. Together these results indicate that an Al-induced increase
in IHVA possibly results from activating cAMP-PKA.
However, H-89 did not reverse the action of AlCl3
totally, suggesting that other mechanisms must contribute to its
action on IHVA at high concentrations.
Platt[7] reported that
the interactions of aluminum with two different binding sites
(within and outside) of calcium channels might contribute to the
reduction of VDCCs on DRG neurons. Al has been reported to inhibit
Mg-dependent enzymes and to interact with phosphorylation sites[18].
In the present study, the co-application of forskolin and Al
did not cancel the reduction and the action of 0.1 mmol/L Al was not
affected by H-89, indicating that the mechanism by which Al reduces
IHVA at low concentrations might not be involved
in the cAMP-PKA system. In addition, Gin B effectively canceled the
increase of IHVA by Al at high con-centrations,
but had almost no effect on the reduction of IHVA
by Al at low concentrations, further suggesting that the action of
Al at low concentrations on IHVA occurs via a
different mechanism. The mechanism by which Al reduced IHVA
requires further examination. At intermediate concentration ranges,
Al both reduced and enhanced IHVA. The mechanism
is not known, but may result from a difference in neurons or from
the concentration of Al itself, which indicated that this
concentration might be the point at which IHVA
moves from being inhibited to enhanced and this might be the reason
for its complexity and diversity.
EGb is a complex mixture
containing 24% flavonoid glycosides, 6% terpene lactones, such as
ginkgolide A, B, C, J and bilobalide, a number of organic acids, and
various other constituents. Studies have shown that Gin B has many
pharmacological effects (ie preventing atherosclerosis, diminishing
coagulation of platelets, ameliorating the circulation system) and
has a distinctively protective effect on the central nerve and
cardiovascular systems. Clinical studies have shown that oral
administration of EGb in human patients with dementia is
effective[19]. Gin B can protect cardio-cmyocytes and
cultured neurons from injury by hypoxia and ischemia through many
pathways, for example, by acting as an anti-oxidant[20],
acting as the antagonist of platelet-activating factor[21]
and by inhibiting NO-stimulated PKC activity[22].
Furthermore, Gin B has been shown to prevent neurons from glutamate
excitoxicity through a reduction in [Ca2+]i[23]
and to have an effect on the glycine-gated chloride channel[24].
The present study provides the first evidence that Gin B can cancel
the increase of IHVA by Al, and that Gin B can
protect neurons by inhibiting IHVA, providing a
possible mechanism for clinical treatment in a number of nervous
system diseases. The detailed mechanism by which Gin B inhibits IHVA
remains to be investigated.
References
- 1 Tokutake S, Nagase H,
Morisaki S, Oyanagi S. Aluminium detected in senile plaques and
neurofibrillary tangles is contained in lipofuscin granules with
silicon, probably as aluminosilicate. Neurosci Lett 1995; 185:
99-102.
- 2 Wisniewski HM. Aluminum, tau
protein, and Alzheimer's disease. Lancet 1994; 344: 204-5.
- 3 Gilbert ME, Shafer TJ. In
vitro exposure to aluminum does not alter long-term
potentiation or glutamate release in rat hippocampal slices.
Neurotoxicol Teratol 1996; 18: 175-80.
- 4 Platt B, Carpenter DO,
Busselberg D, Reymann KG, Riedel G. Aluminum impairs hippocampal
long-term potentiation in rats in vitro and in vivo.
Exp Neurol 1995; 134: 73-86.
- 5 Zou BD, Xiao HM, Zhang ZD, Li
A. Effect of aluminum on evoked potential on hippocampal CA3
area in rats. J Tongji Med Univ 1998; 27: 15-18.
- 6 Matyja E. Aluminum enhances
glutamate-mediated neurotoxicity in organotypic cultures of rat
hippocampus. Folia Neuropathol 2000; 38: 47-53.
- 7 Platt B, B¨¹sselberg D.
Actions of aluminium on voltage-activated calcium channel
currents. Cell Mol Neurobiol 1994; 14: 819-29.
- 8 Trombley, PQ. Selective
modulation of GABAA receptors by aluminum. J
Neurophysiol 1998; 80: 755-61.
- 9 Platt B, Haas H, B¨¹sselberg
D. Aluminum reduces glutamate-activated currents of rat
hippocampal neurons. Neuroreport 1994; 5: 2329-32.
- 10 Zhang ZX, Qi XY, Xu YQ.
Effect of ginkgolide B on L-type calcium current and cytosolic
[Ca2+]i in guinea pig ischemic ventricular
myocytes. Acta Physiol Sin 2003; 55: 24-8.
- 11 Bastianetto S, Quirion R.
EGb 761 is a neuroprotective agent against beta-amyloid
toxicity. Cell Mol Biol 2002; 48: 693-7.
- 12 Wu XF, Wang QJ, Lou FC.
Protective effect of Ginkgolides on rat focal brain
ischemia. J China Pharm Univ 2001; 32: 141-5.
- 13 Xu CQ, Zhang ZM, Xia ZL, Wu
CH, Zhou PA. Acute isolation and identification of CA1 pyramidal
neurons in hippocampus of rats. Chin J Appl Physiol 1999; 15:
189-91.
- 14 Savory J, Herman MM, Ghribi
O. Intracellular mechanisms underlying aluminum-induced
apoptosis in rabbit brain. J Inorg Biochem 2003; 97: 151-4.
- 15 Deisseroth K, Heist EK,
Tsien RW. Translocation of calmodulin to the nucleus supports
CREB phosphorylation in hippocampal neurons. Nature 1998; 392:
198-202.
- 16 Morgan SL, Teyler TJ. VDCCs
and NMDARs underline two forms of LTP in CA1 hippocampus in
vivo. J Neurophysiol 1999; 82: 736-40.
- 17 Kavalali ET, Hwang KS,
Plummer MR. cAMP-dependent enhancement of dihydropyridine-sensitive
calcium channel availability in hippocampal neurons. J Neurosci
1997; 17: 5334-48.
- 18 Macdonald TL, Martin RB.
Aluminum ion in biological systems. Trends Biochem Sci 1988; 13:
15-19.
- 19 Le Bars PL, Katz MM, Berman
N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled,
doubled-blind, randomized trial of an extract of Ginkgo
biloba for dementia. J Am Med Assoc 1997; 278: 1327-32.
- 20 Lenoir M, Pedruzzi E, Rais
S, Drieu K, Perianin A. Sensitization of human neutrophil
defense activities through activation of platelet-activating
factor receptors by ginkgolide B, a bioactive component of the
Ginkgo biloba extract EGB 761. Biochem Pharmacol 2002;
63: 1241-9.
- 21 Bastianetto S, Zheng WH,
Quirion R. The Ginkgo biloba extract (EGb 761) protects
and rescues hippocampal cells against nitric oxide-induced
toxicity: involvement of its flavonoid constituents and protein
kinase C. J Neurochem 2000; 74: 2268-77.
- 22 Zhu L, Wu J, Liao H, Gao J,
Zhao XN, Zhang ZX. Antagonistic effects of extract from leaves
of Ginkgo biloba on glutamate neurotoxicity. Acta
Pharmacol Sin 1997; 18: 344-7.
- 23 Kondratskaya EL, Lishko PV,
Chatterjee SS, Krishtal OA. BN52021, a platelet activating
factor antagonist, is a selective blocker of glycine-gated
chloride channel. Neurochem Int 2002; 40: 647-53.
- 24 Chatterjee SS, Kondratskaya
EL, Krishtal OA. Structure-
activity studies with Ginkgo biloba extract constituents
as receptor-gated chloride channel blockers and modulators.
Pharma-copsychiatry 2003; 36: S68-77.
|